LAVA Therapeutics NV corporate insiders have only been selling lately: one insider sold about $3.2 million of stock over 12 months, with no open-market purchases.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 20, 2025 | Cooperatieve Gilde Healthcare IV U.A. | 10% Owner | Sell | 690,239 | $1.49 | $1.0M | SEC |
| Oct 20, 2025 | Cooperatieve Gilde Healthcare IV U.A. | 10% Owner | Sell | 1,181,131 | $1.47 | $1.7M | SEC |
| Oct 15, 2025 | Cooperatieve Gilde Healthcare IV U.A. | 10% Owner | Sell | 47,686 | $1.54 | $73K | SEC |
| Oct 15, 2025 | Cooperatieve Gilde Healthcare IV U.A. | 10% Owner | Sell | 227,341 | $1.51 | $343K | SEC |
| Oct 10, 2025 | Gilde Healthcare Holding B.V. | 10% Owner | Sell | 48,169 | $1.56 | $75K | SEC |
| Oct 10, 2025 | Gilde Healthcare Holding B.V. | 10% Owner | Sell | 28,954 | $1.57 | $45K | SEC |
| Oct 10, 2025 | Gilde Healthcare Holding B.V. | 10% Owner | Sell | 49,869 | $1.55 | $77K | SEC |
| Sep 23, 2025 | Versant Vantage I, L.P. | 10% Owner | Sell | 2,370,533 | $1.40 | $3.3M | SEC |
| Sep 23, 2025 | Versant Vantage I, L.P. | 10% Owner | Sell | 532,870 | $1.40 | $746K | SEC |
| Sep 18, 2025 | Versant Vantage I GP-GP, LLC | 10% Owner | Sell | 362,806 | $1.49 | $541K | SEC |
| Sep 18, 2025 | Versant Vantage I GP-GP, LLC | 10% Owner | Sell | 366,111 | $1.44 | $527K | SEC |
| Sep 18, 2025 | Versant Vantage I GP-GP, LLC | 10% Owner | Sell | 307,707 | $1.53 | $471K | SEC |
| Sep 18, 2025 | Versant Vantage I GP-GP, LLC | 10% Owner | Sell | 192,293 | $1.53 | $294K | SEC |
| Sep 18, 2025 | Versant Vantage I GP-GP, LLC | 10% Owner | Sell | 228,791 | $1.44 | $329K | SEC |
| Sep 18, 2025 | Versant Vantage I GP-GP, LLC | 10% Owner | Sell | 226,726 | $1.49 | $338K | SEC |
In the last 12 months LAVA Therapeutics NV insiders made open-market purchases worth about $0 and sales worth about $3.2 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in LVTX was filed on 2025-10-20.
No congressional trades in LVTX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).